Creative Biolabs Expands IVD Capabilities with Integrated Protein and Nucleic Acid Detection
Creative Biolabs has enhanced its in vitro diagnostics services by integrating protein and nucleic acid detection technologies, offering researchers more comprehensive biomarker analysis for early disease detection and complex condition research.
Creative Biolabs has significantly expanded its in vitro diagnostics capabilities through the integration of protein and nucleic acid detection technologies, addressing the growing need for comprehensive biomarker analysis in disease research. The company now offers systematic protein-level detection services that provide researchers with reliable data even from limited sample volumes, leveraging proteins as direct mediators of physiological and pathological processes.
According to a company expert, protein level studies track disease onset and development more rapidly than genetic testing alone, with high-sensitivity technology platforms ensuring stable and reproducible results. The expansion includes a full range of flexible protein biomarker detection services employing multiple disciplines such as ELISA, multiplex assays, mass spectrometry, and protein arrays for quantitative target detection and large-scale proteomics.
Recognizing that single biomarkers often cannot capture disease complexity, Creative Biolabs has developed innovative combined nucleic acid and protein detection services that analyze both signals simultaneously in a single assay. This integrated approach conserves sample volume and time while revealing cross-level molecular interactions, enhancing the rationale for early disease detection and clinical assessment in complex conditions such as pancreatic cancer and cardiovascular disease.
The company emphasizes rigorous quality control throughout every step from sample preparation to data interpretation, ensuring reliable, high-quality data that meets researchers' standards for detection sensitivity. This expansion positions Creative Biolabs at the forefront of molecular diagnostics innovation, potentially shaping the future of in vitro diagnostics through integrated biomarker analysis.